Xeljanz Oral Solution (tofacitinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL**		**IF RENEWAL:** DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Xeljanz Oral Solution (tofacitinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
□ Moderately to severely active rheumatoid arthritis □ Psoriatic arthritis □ Polyarticular juvenile idiopathic arthritis(pJIA) □ Other diagnosis: _____ICD-10_____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient using drug as part of a clinical trial? □ Yes □ No

<u>Initial Request</u>:
Does patient have an enteral feeding tube? □ Yes □ No

Does patient have difficulty swallowing? □ Yes □ No *Please submit documentation*.

Is the patient currently not taking any other tablets or capsules (Exception: orally dissolving tablets and sprinkle capsules)? □ Yes □ No

Prescriber specialty:
Select if the requested medication is prescribed by one of the following specialists:
- **□ Dermatologist**
- **□ Rheumatologist**

Has the patient tried and had an inadequate response to at least a three month trial with the biosimilar for Humira- adalimumab-aacf? □ Yes □ No **Must submit prior dates of use.*

Will the patient avoid concomitant therapy with another biologic or immunomodulatory agent such as Kineret, Remicade , Rituxan, Orencia, Cimzia, Enbrel, Humira, Actemra or Simponi, etc.) or non-biologic agents (apremilast etc.) or JAK-inhibitors (upadacitinib, baricitinib, fedratinib, ruxolitinib)? □ Yes □ No

For <u>moderately to severely active rheumatoid arthritis</u>, also answer the following:

Has the patient had a trial and inadequate response to methotrexate or another oral non-biologic disease modifying anti-rheumatic drug (DMARD) such as Imuran, Ridaura, Plaquenil, sulfasalazine or Arava?* □ Yes □ No
****Must submit documentation.***

Is the patient unable to take the prerequisite non-biologic DMARD due to their chronic liver disease (such as chronic hepatitis, fatty liver, nonalcoholic steatohepatitis (NASH) or elevated liver enzymes)?* □ Yes □ No
****Must submit documentation.***

Xeljanz Oral Solution (tofacitinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

For psoriatic arthritis, also answer the following:
Has the patient had a trial and inadequate response to methotrexate or another oral non-biologic disease modifying anti-rheumatic drug (DMARD) such as sulfasalazine(Azulfidine®), leflunamide(Arava®) , or cyclosporine?
□ Yes □ No *Must submit prior dates of use*

For polyarticular juvenile arthritis, also answer the following:
Has the patient tried and had an inadequate response or intolerance to an oral disease modifying anti-rheumatic agent [e.g., methotrexate, sulfasalazine, or leflunomide (Arava)]? □ Yes □ No

Is the patient unable to take a non-biologic DMARD due to chronic liver disease (such as chronic hepatitis, fatty liver, nonalcoholic steatohepatitis/NASH, or elevated liver enzymes)? □ Yes □ No

If "No" to the above question, provide the rationale explaining why the patient cannot take the prerequisite DMARDs: _____

Reauthorization:
Is the patient currently taking any other tablets or capsules (Exception: orally dissolving tablets and sprinkle capsules)? □ Yes □ No

If yes, please provide rationale (if applicable), explaining why the patient is unable to take regular oral tablets or capsules:

_____

Select if the requested medication is prescribed by one of the following specialists:
- □ **Dermatologist**
- □ **Rheumatologist**

Does the patient continue to have a positive clinical response and is remission of disease maintained with continued use?* □ Yes □ No
Must provide supporting chart notes.

Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent? □ Yes □ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

Xeljanz Oral Solution (tofacitinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909